The evaluation of drug combinations for cancer treatment has progressed slowly through methodical clinical research. A new study examining gene expression profiles could signal a shift in the approach to combination therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
LeClerc, J.M. et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J. Clin. Oncol. 20, 237–246 (2002).
Pui, C.H. & Evans, W.E. Acute lymphoblastic leukemia. N. Engl. J. Med. 339, 605–615 (1998).
Cheok, M.H. et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat. Genet. 34, 85–90 (2003).
Gorre, M.E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876–880 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Golub, T. Mining the genome for combination therapies. Nat Med 9, 510–511 (2003). https://doi.org/10.1038/nm0503-510
Issue Date:
DOI: https://doi.org/10.1038/nm0503-510
This article is cited by
-
EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model
Journal of Molecular Medicine (2007)
-
Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy
Nature Reviews Cancer (2006)
-
Death receptors in chemotherapy and cancer
Oncogene (2004)
-
Moving towards individualized medicine with pharmacogenomics
Nature (2004)